Upload new images. The image library for this site will open in a new window.
Upload new documents. The document library for this site will open in a new window.
Show web part zones on the page. Web parts can be added to display dynamic content such as calendars or photo galleries.
Choose between different arrangements of page sections. Page layouts can be changed even after content has been added.
Move this whole section down, swapping places with the section below it.
Check for and fix problems in the body text. Text pasted in from other sources may contain malformed HTML which the code cleaner will remove.
Accordion feature turned off, click to turn on.
Accordion featurd turned on, click to turn off.
Change the way the image is cropped for this page layout.
Cycle through size options for this image or video.
Align the media panel to the right/left in this section.
Open the image pane in this body section. Click in the image pane to select an image from the image library.
Open the video pane in this body section. Click in the video pane to embed a video. Click ? for step-by-step instructions.
Remove the image from the media panel. This does not delete the image from the library.
Remove the video from the media panel.
Ulhas Naik is a professor in the Department of Biological Sciences and director of the Delaware Cardiovascular Research Center based at UD.
So many of us have lost loved ones to heart disease and stroke. According to the American Heart Association, someone dies from a heart attack every minute in the United States, and stroke kills an American about every four minutes.
Ulhas Naik, director of the Delaware Cardiovascular Research Center based at the University of Delaware, is now on the trail of what may be a key accomplice to these leading killers of humankind.
Naik's focus is ASK1 (apoptosis signal-regulating kinase 1), an enzyme found in blood platelets, the tiny cells that rush to the scene to form a clot where a blood vessel is injured or a plaque inside an artery has ruptured. Naik has received a four-year, $1.53 million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to support the research project.
"What's so interesting about ASK1 is that it is activated only by stress," Naik says. "When under stress, ASK1 signals other proteins critical to cell survival to stimulate the platelets to get to work."
After they are made in your body's bone marrow, platelets circulate in the blood stream, where they live for eight to 10 days. When an injury occurs, these tiny disks start sticking to the wound site and put out tentacles that help them clump together to plug the leak. While clot formation is critical for getting a cut finger to stop bleeding, it can be deadly inside a blood vessel when it prevents blood flow, causing a heart attack or stroke.
"In our laboratory studies, we've found for the first time that lots of ASK1 protein is expressed in platelets and is rapidly activated when a blood vessel is injured or is under stress from free radicals or from a lack of oxygen, for example. We believe this is an important stress-response signaling pathway," Naik notes.
In his laboratories in UD's Department of Biological Sciences and at the Delaware Biotechnology Institute, Naik and his research team are working to synthesize a new compound to block the ASK1 function and thus inhibit the platelets' clotting function. Key to the project's success will be formulating the inhibitor in such a way that it will stop excess clot, or thrombus, formation without affecting the beneficial process of wound healing.
"We're taking a step forward in developing a new thrombotic drug," Naik says. "My goal is not to make money, but to find something that will help control devastating diseases like stroke and atherosclerosis."
Naik knows the heartbreak of these killers firsthand. Three of his brothers have died from heart attacks.
About project support
The research reported in this news story is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) under NIH grant award number RO1HL11318801A1.
Move this whole section up, swapping places with the section above it.